Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.

Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J., Van Vlierberghe, H., Trojan, J., Kolligs, F., Weiss, A., Miles, S., Gasbarrini, A., Lencioni, M., Cicalese, L., Sherman, M., Gridelli, C., Buggisch, P., Gerken, G., Schmid, R., Boni, C., Personeni, N., Hassoun, Z., Abbadessa, G., Schwartz, B., Von Roemeling, R., Lamar, M., Chen, Y., Porta, C., Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, <<THE LANCET ONCOLOGY>>, 2013; 14 (1): 55-63. [doi:10.1016/S1470-2045(12)70490-4] [http://hdl.handle.net/10807/52153]

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Gasbarrini, Antonio;
2013

Abstract

Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.
2013
Inglese
Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J., Van Vlierberghe, H., Trojan, J., Kolligs, F., Weiss, A., Miles, S., Gasbarrini, A., Lencioni, M., Cicalese, L., Sherman, M., Gridelli, C., Buggisch, P., Gerken, G., Schmid, R., Boni, C., Personeni, N., Hassoun, Z., Abbadessa, G., Schwartz, B., Von Roemeling, R., Lamar, M., Chen, Y., Porta, C., Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, <<THE LANCET ONCOLOGY>>, 2013; 14 (1): 55-63. [doi:10.1016/S1470-2045(12)70490-4] [http://hdl.handle.net/10807/52153]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/52153
Citazioni
  • ???jsp.display-item.citation.pmc??? 234
  • Scopus 487
  • ???jsp.display-item.citation.isi??? 460
social impact